Two months after U.S. President Donald Trump issued an executive order proclaiming diversity, equity and inclusion (DEI) programs “illegal and immoral,” Roche has scrapped its high-profile ...

Die Mitarbeitenden des Basler Pharmakonzerns Roche haben heute ein einseitiges Schreiben erhalten. Darin ist zu lesen, dass die «Chief Diversity Offices» in den USA und Basel umbenannt und neu ...

Roche has secured its third antibody-drug conjugate pact of the year, this time agreeing to hand $36 million in upfront payments to Oxford BioTherapeutics. The agreement will also see U.K.-based ...

ZURICH, March 19 (Reuters) - Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse panels for U.S. hiring, the latest companies ...

The recall affects acne creams from well-known retailers such as Walgreens, La Roche-Posay, and Proactiv. The U.S. Food and Drug Administration (FDA) issued a recall notice on March 11th ...

Some popular skin care products, acne treatments, are being voluntarily recalled because they may contain elevated levels of a chemical that causes cancer, according to a notice posted this week ...

Acne creams from retailers including Walgreens, La Roche-Posay and Proactiv have been voluntarily recalled due to elevated levels of a potentially cancer-causing agent. The U.S. Food and Drug ...

Proactiv Skin Smoothing Exfoliator and La Roche-Posay Effaclar Duo Dual Action Acne Treatment. The full list and lot numbers was posted online Tuesday. “Even with daily use of these products for ...

Acne creams from retailers including Walgreens, La Roche-Posay and Proactiv have been voluntarily recalled due to elevated levels of a potentially cancer-causing agent. The U.S. Food and Drug ...

Some La Roche-Posay, Proactiv and Walgreens Acne Treatments Recalled Due to Benzene Levels WASHINGTON (AP) — U.S. health officials are asking retailers to pull a small number of acne creams from ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipeline. The outlay, plus up to $3.6 billion in milestones, has secured Roche the right to codevelop and ...